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tests from Panama City versus other areas of Panama and 
might result in a sampling bias. Despite these limitations, 
the recent Zika outbreak has shown the speed at which vec-
torborne diseases can spread and highlights the importance 
of detecting emerging viruses like PTVs.
Acknowledgments
We thank staff in the Department of Research in Virology and 
Biotechnology at the Gorgas Memorial Institute for Health  
Studies in Panama and in the Ministry of Health National  
Epidemiology Department for the surveillance data and outbreak 
response during 2009. We also thank Meghan Tipre for help 
creating the epidemiologic map. 
This work was done in compliance with the Gorgas Bioethics 
Committee (1010/CBI/ICGES/15). 
Funding was provided by the Panama Ministry of Economy 
and Finance (09.044.051 to S.L.-V. and 09.044.050 to J.M.P.); 
the Secretaría Nacional de Ciencia, Tecnología, e Innovación 
(SENACYT; FID-09-103 to J.-P.C); and Gorgas Memorial  
Institute, University of Alabama at Birmingham (to N.D.G.). 
J.M.P. and S.L.-V. are members of the Sistema Nacional de 
Investigación (SNI) of SENACYT in Panama.
Dr. Gundacker is an infectious disease fellow at the University 
of Alabama at Birmingham. His primary interest are the clinical 
description of febrile tropical infectious diseases, laboratory 
differential diagnosis of these diseases, and host–pathogen 
interactions. Mr. Carrera is an epidemiologist and virologist at 
Gorgas Memorial Institute. His primary research interests are 
ecology, evolution, and epidemiology of arthropodborne and 
zoonotic viruses. 
References
  1. Armien B, Pascale JM, Munoz C, Lee SJ, Choi KL, Avila M, et al. 
Incidence rate for hantavirus infections without pulmonary  
syndrome, Panama. Emerg Infect Dis. 2011;17:1936–9.  
http://dx.doi.org/10.3201/eid1710.101717
  2. Fauci AS, Morens DM. Zika virus in the Americas—yet  
another arbovirus threat. N Engl J Med. 2016;374:601–4.  
http://dx.doi.org/10.1056/NEJMp1600297
  3. Tesh RB, Chaniotis BN, Peralta PH, Johnson KM. Ecology of  
viruses isolated from Panamanian phlebotomine sandflies.  
Am J Trop Med Hyg. 1974;23:258–69.
  4. Palacios G, Wiley MR, Travassos da Rosa AP, Guzman H,  
Quiroz E, Savji N, et al. Characterization of the Punta Toro species 
complex (genus Phlebovirus, family Bunyaviridae). J Gen Virol. 
2015;96:2079–85. http://dx.doi.org/10.1099/vir.0.000170
  5. Xu F, Chen H, Travassos da Rosa AP, Tesh RB, Xiao SY.  
Phylogenetic relationships among sandfly fever group viruses 
(Phlebovirus: Bunyaviridae) based on the small genome segment.  
J Gen Virol. 2007;88:2312–9. http://dx.doi.org/10.1099/vir.0.82860-0
  6. Liu DY, Tesh RB, Travassos Da Rosa AP, Peters CJ, Yang Z,  
Guzman H, et al. Phylogenetic relationships among members  
of the genus Phlebovirus (Bunyaviridae) based on partial M  
segment sequence analyses. J Gen Virol. 2003;84:465–73.  
http://dx.doi.org/10.1099/vir.0.18765-0
  7. Sánchez-Seco MP, Echevarría JM, Hernández L, Estévez D,  
Navarro-Marí JM, Tenorio A. Detection and identification  
of Toscana and other phleboviruses by RT–nested-PCR assays  
with degenerated primers. J Med Virol. 2003;71:140–9.  
http://dx.doi.org/10.1002/jmv.10465
  8. Kumar S, Stecher G, Tamura K. MEGA7: Molecular Evolutionary 
Genetics Analysis version 7.0 for bigger datasets. Mol Biol Evol. 
2016;33:1870–4. http://dx.doi.org/10.1093/molbev/msw054
  9. Valderrama A, Tavares MG, Andrade Filho JD. Anthropogenic  
influence on the distribution, abundance and diversity of sandfly  
species (Diptera: Phlebotominae: Psychodidae), vectors of  
cutaneous leishmaniasis in Panama. Mem Inst Oswaldo Cruz. 2011; 
106:1024–31. http://dx.doi.org/10.1590/S0074-02762011000800021
Address for correspondence: Sandra López-Vergès, Gorgas Memorial 
Institute for Health Studies, Department of Research in Virology and 
Biotechnology, Ave Justo Arosemena and St 35, No. 0816-02593, 
Panama City, Panama; email: slopez@gorgas.gob.pa
mcr-1 Colistin Resistance in 
ESBL-Producing Klebsiella 
pneumoniae, France
Yvan Caspar, Mylène Maillet, Patricia Pavese, 
Gilles Francony, Jean-Paul Brion,  
Marie-Reine Mallaret, Richard Bonnet,  
Frédéric Robin, Racha Beyrouthy, Max Maurin
Author affiliations: Centre Hospitalier Universitaire Grenoble-
Alpes, Grenoble, France (Y. Caspar, M. Maillet, P. Pavese,  
G. Francony, J.-P. Brion, M.-R. Mallaret, M. Maurin); University 
Grenoble Alpes, CNRS, Grenoble; Centre Hospitalier Universitaire 
Clermont-Ferrand, Clermont-Ferrand, France (R. Bonnet, F. Robin,  
R. Beyrouthy); Centre National de Référence de la Résistance 
aux Antibiotiques, Clermont-Ferrand (R. Bonnet, F. Robin,  
R. Beyrouthy); Université Clermont Auvergne, Clermont-Ferrand  
(R. Bonnet, F. Robin, R. Beyrouthy); Institut National de la Santé et 
de la Recherche Médicale, Clermont-Ferrand (R. Bonnet, F. Robin, 
R. Beyrouthy); Institut National de la Recherche Agronomique, 
Clermont-Ferrand (R. Bonnet, F. Robin, R. Beyrouthy)
DOI: http://dx.doi.org/10.3201/eid2305.161942
We report intestinal carriage of an extended-spectrum 
β-lactamase−producing Klebsiella pneumoniae strain 
with high-level resistance to colistin (MIC 24 mg/L) in a 
patient in France who had been hospitalized for fungal 
meningitis. The strain had the mcr-1 plasmid gene and 
an inactivated mgrB gene, which are associated with 
colistin resistance.
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Resistance to colistin in gram-negative bacteria stems mainly from structural modifications of bacterial li-
popolysaccharide. These modifications include addition 
of 4-amino-4-deoxy-l-arabinose or phosphoethanolamine 
caused by chromosomal mutations in genes encoding the 
2-component systems PhoPQ and PmrAB, or mutations in 
the mgrB gene, a negative regulator of PhoPQ (1).
The recent discovery of a horizontally transferable 
plasmid-mediated mcr-1 gene encoding a phosphoetha-
nolamine transferase is a cause for concern, but few mcr-
1−positive clinical strains of Klebsiella pneumoniae have 
been reported so far in Europe (2). Colocalization of car-
bapenemases or extended-spectrum β-lactamase (ESBL) 
genes and the mcr-1 gene on the same plasmids is of con-
cern because it might lead to pandrug resistance (1,3). We 
report mcr-1 colistin resistance in ESBL-producing K. 
pneumoniae isolated from a patient in France.
The patient was a 38-year-old man who had chronic 
granulomatous disease that was diagnosed when he was 
8 months old. Since then, he has had several minor and 
major diseases and conditions, including primitive fem-
oral osteitis, hepatic abscesses, disseminated candidia-
sis, and bacteremia, which required several treatments 
with antimicrobial drugs. However, the patient was nev-
er given colistin.
In April 2016, he was hospitalized for surgical removal 
of a thyroid abscess. Fungal cultures of the abscess grew 
Aspergillus fumigatus. Despite antifungal treatment with 
amphotericin B and flucytosine, fungal meningitis, cerebral 
arterial vasospasm at the Willis polygon, and hydrocepha-
lus developed. The patient also received immunosuppres-
sive therapy (methylprednisolone and anakinra) and em-
piric antimicrobial drug therapy, including cotrimoxazole, 
clindamycin, meropenem, and vancomycin successively.
In August 2016, systematic culture of a rectal swab 
specimen showed an ESBL-producing strain of K. pneu-
moniae; 2 previous rectal screenings showed negative re-
sults. The strain was resistant to colistin (MIC >4 mg/L). 
Resistance was determined by using a broth microdilution 
assay (BD Phoenix Instrument; Becton Dickinson, Frank-
lin Lakes, NJ, USA) (online Technical Appendix, https://
wwwnc.cdc.gov/EID/article/23/5/16-1942-Techapp1.pdf). 
An MIC of 24 mg/L was found for polymyxin B by using 
the E-test method (Polymyxin B E-test strip; bioMérieux, 
Marcy L’Etoile, France).
The strain was sent to the French National Reference 
Center for Antibiotic Resistance in Enterobacteriaceae (Hôpi-
tal Gabriel Montpied, Clermont-Ferrand, France), which con-
firmed phenotypic resistance to colistin and identified the mcr-
1 gene by using PCR and previously described primers (2). 
Whole-genome sequencing showed that the K. pneumoniae 
strain had genotype ST15 and confirmed the presence of the 
mcr-1 gene on a 33,303-kb transferable plasmid of incompati-
bility group IncX4 (online Technical Appendix). This plasmid 
differed by only 4 mutations from mcr-1.2−encoding plasmid 
pMCR-1.2.IT (GenBank accession no. KX236309) previ-
ously characterized in Italy (4). Conjugation of the plasmid 
into Escherichia coli K12 conferred colistin resistance (MIC 
increased from 0.25 mg/L to 4 mg/L) to the E. coli strain.
Other resistance genes were also identified (Table), in-
cluding the ESBL-encoding gene blaSHV106 (online Techni-
cal Appendix). None of them were localized with the mcr-1 
gene on the IncX4 plasmid. Moreover, insertion of mobile 
element IS5 in the mgrB gene was detected, which is also 
associated with colistin resistance (5). No mutations were 
found in the prmA, prmB, phoP, and phoQ genes.
There is currently no commercial medium to screen 
gram-negative bacteria harboring the mcr-1 gene. Nor-
dmann et al. (6) described an in-house SuperPolymyxin 
medium composed of eosin methylene blue agar, 3.5 mg/L 
of colistin sulfate, 10 mg/L of daptomycin, and 5 mg/L am-
photericin B, which showed excellent sensitivity and speci-
ficity. Colistin resistance can be confirmed within 2 h by us-
ing an in-house rapid polymyxin Nordmann-Poirel test (7). 
The mcr-1 gene can be rapidly detected by real-time PCR 
of DNA extracts obtained from bacterial strains or directly 
from stool samples (2,8,9).
We obtained subcultures of the strain from the patient 
on Columbia CNA agar containing 10 mg/L of colistin and 
15 mg/L of nalidixic acid and 5% sheep blood (CNA+; bio-
Mérieux) but not on Thayer-Martin agar medium contain-
ing unknown concentrations of vancomycin, colistin, am-
photericin B, and trimethoprim (VCA3; bioMérieux). Lack 
of growth on this medium might be related to a high colis-
tin concentration or the presence of vancomycin, which can 
potentiate colistin activity (6). Further investigations using 





Table. Resistance genes identified by whole-genome sequencing of an ESBL-producing mcr-1positive Klebsiella pneumoniae strain 
isolated from a 38-year-old man, France* 
Resistance gene Target antimicrobial drug 
mcr-1 and inactivation of mgrB by IS5 insertion Colistin 
blaSHV-106 β-lactams 
aac(3)-IId and aadA16-like Aminoglycoside 
aac(6)Ib-cr Quinolone and aminoglycoside 
fosA5 Fosfomycin 
sulI and folP Sulfonamide 
dfrA27 Trimethoprim 
tetD Tetracycline 
*ESBL, extended-spectrum β-lactamase. 
 
CNA+ medium did not identify intestinal carriage of ES-
BL-negative but mcr-1−positive enterobacteria in the index 
case-patient. On the basis of these results, rectal screening 
of 39 contacts was performed by using an ESBL-screening 
medium (BLSE agar [MacConkey agar and Drigalski agar]; 
bioMérieux). All of the tests showed negative results.
The origin of the mcr-1 strain remains unknown. Nos-
ocomial acquisition cannot be ruled out because colistin-
resistant strains harboring the mcr-1 gene might have been 
isolated in the hospital but not identified because this resis-
tance mechanism was initially reported in February 2016. 
Food might also be incriminated (1); one study identified a 
21% mcr-1 prevalence among ESBL-producing E. coli in 
calves in France (10).
Multiple antimicrobial drug therapy for this patient 
might have selected for this multidrug-resistant bacte-
ria. The presence of a plasmid containing the mcr-1 and 
ESBL or other resistance genes in the same strain might 
be involved in selection of colistin-resistant strains dur-
ing administration of any ineffective antimicrobial drug 
(3). Development of efficient tools for rapid detection of 
mcr-1−harboring strains should be a priority to prevent dis-
semination of these strains in hospital settings.
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We identified rmtE1, an uncommon 16S ribosomal methyl-
transferase gene, in an aminoglycoside- and cephalospo-
rin-resistant Escherichia coli sequence type 448 clinical 
strain co-harboring blaCMY-2. Long-read sequencing re-
vealed insertion of a 101,257-bp fragment carrying both 
resistance genes to the chromosome. Our findings under-
score E. coli sequence type 448 as a potential high-risk 
multidrug-resistant clone.
RmtE (RmtE1 and its variant RmtE2) is an uncommon plasmid-mediated 16S rRNA methyltransferase (16S 
RMTase) found in gram-negative bacteria; only 4 strains 
have been reported to produce RmtE, all Escherichia coli, 
including 1 from the University of Pittsburgh Medical 
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